Skip to main content

Table 1 Clinical characteristics of elderly-onset RA at initiation of TNFi or IL-6i

From: Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study

Characteristic TNFi
(n = 674)
IL-6i
(n = 297)
P value
Age, median years (IQR) 71 (67–77) 72 (67–77) 0.34
Female sex, n (%) 513 (76.1) 221 (74.4) 0.57
Disease duration, median months (IQR) 32 (12–77) 39 (16–79) 0.12
CRP (mg/dL), median (IQR) 1.0 (0.20–3.1) 1.74 (0.30–4.5) 0.02
RF-positive, n (%) 452 (72.6) 200 (73.5) 0.81
ACPA-positive, n (%) 396 (73.1) 172 (74.8) 0.66
Tender joint count, median (IQR) 3 (1–6) 2 (1–5) 0.47
Swollen joint count, median (IQR) 3 (1–6) 2 (1–4) 0.36
PtGA VAS (0–100 mm), median (IQR) 54 (30–74) 54 (30–74) 0.82
PGA VAS (0–100 mm), median (IQR) 34 (19–55) 35 (19–54) 0.99
DAS28-ESR, median (IQR) 4.6 (3.7–5.5) 4.6 (3.6–5.5) 0.66
SDAI, median (IQR) 17 (11–25) 16 (10–25) 0.75
CDAI, median (IQR) 16 (10–23) 14 (10–22) 0.29
HAQ-DI, median (IQR) 1.0 (0.38–1.75) 1.0 (0.38–1.88) 0.65
Concurrent methotrexate use, n (%) 417 (61.9) 140 (47.1) < 0.001
Methotrexate dosage (mg/week), median (IQR) 8 (6–10) 8 (6–10) 0.99
Glucocorticoid use, n (%) 259 (38.4) 141 (47.4) 0.009
Glucocorticoid dosage (mg/day), median (IQR) 5.0 (3.0–7.0) 5.0 (4.0–8.0) 0.52
Sulfasalazine use, n (%) 152 (22.6) 70 (23.6) 0.74
Other csDMARDs use, n (%) 110 (16.4) 73 (24.8) 0.003
1st bDMARD (%) 430 (63.8) 127 (42.8) < 0.001
2nd bDMARD (%) 164 (24.3) 88 (29.6) 0.12
≥3rd bDMARD (%) 80 (11.9) 82 (27.6) < 0.001
  1. Data are no. (%) patients or median IQR
  2. Demographic and clinical characteristics at initiation of TNFi or IL-6i summarized as median for continuous data and as numbers (percentages) for categorical data. T test or Wilcoxon signed-rank test and the chi-squared test were used to compare the clinical characteristics between the 2 groups for continuous variables and categorical variables, respectively. ACPA anti-citrullinated protein antibodies, bDMARDs biological disease-modifying antirheumatic drugs, csDMARDs conventional synthetic DMARDs, CDAI clinical disease activity index, CRP C-reactive protein, DAS28-ESR Disease Activity Score 28-erythrocyte sedimentation rate, EORA elderly-onset rheumatoid arthritis, IL-6i interleukin-6 inhibitors, HAQ-DI Health Assessment Questionnaire Disability Index, PtGA patient global assessment, PGA physician global assessment, RF rheumatoid factor, SDAI simplified disease activity index, TNFi tumor necrosis factor inhibitors, YORA young-onset rheumatoid arthritis, VAS visual analogue scale